Journal
CLINICAL INFECTIOUS DISEASES
Volume 51, Issue -, Pages S176-S182Publisher
OXFORD UNIV PRESS INC
DOI: 10.1086/653518
Keywords
-
Categories
Funding
- Cubist
- GlaxoSmithKline
- Merck
- Cubist Pharmaceuticals
Ask authors/readers for more resources
The evolution of methicillin-resistant and vancomycin-resistant Staphylococcus aureus has demanded serious review of antimicrobial use and development of new agents and revised approaches to prevent and overcome drug resistance. Depending on local conditions and patient risk factors, empirical therapy of suspected S. aureus infection may require coverage of drug-resistant organisms with newer agents and novel antibiotic combinations. The question of treatment with inappropriate antibiotics raises grave concerns with regard to methicillin-resistant S. aureus selection, overgrowth, and increased virulence. Several strategies to reduce the nosocomial burden of resistance are suggested, including shortened hospital stays and outpatient parenteral antimicrobial therapy of the most serious infections.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available